Matrix-metalloproteinase-2, -8 and -9 in serum and skin blister fluid in patients with severe sepsis by Gäddnäs, Fiia P et al.
Gäddnäs et al. Critical Care 2010, 14:R49
http://ccforum.com/content/14/2/R49
Open Access RESEARCH
© 2010 Gäddnäs et al.; licensee Biomed Central, Ltd. This is an open access article distributed under the terms of the Creative Commons
attribution license (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
Research Matrix-metalloproteinase-2, -8 and -9 in serum and 
skin blister fluid in patients with severe sepsis
Fiia P Gäddnäs*1, Meeri M Sutinen2, Marjo Koskela1, Taina Tervahartiala3, Timo Sorsa3, Tuula A Salo2, Jouko J Laurila1, 
Vesa Koivukangas4, Tero I Ala-Kokko†1 and Aarne Oikarinen†5
Abstract
Introduction: Matrix metalloproteinases (MMPs) have various roles in inflammatory states. They seem to be able to 
modulate endothelial barriers and regulate the activity of chemokines and cytokines. The timely development of the 
levels during severe sepsis and thereafter have not been investigated. In addition it was of interest to study alterations 
of MMP-levels in intact skin, as the skin is the largest barrier against external pathogens and MMPs have not been 
studied at organ level in human sepsis. The aim of this study was to investigate the timely development of serum and 
skin MMP-2, -8 and -9 levels in human severe sepsis and their association with disease severity and mortality.
Methods: Forty-four patients with severe sepsis and fifteen healthy controls were included in this prospective 
longitudinal study. The amounts of MMP-2, -8 and -9 were analyzed from serum at days 1, 4, 6, 8, and 10, and from skin 
suction blister fluid at days 1 and 5 from the beginning of severe sepsis. Additionally, samples from the survivors were 
obtained after three and six months.
Results: The levels of MMP-2 and -8 were up-regulated in severe sepsis in comparison to healthy controls in skin blister 
fluid and serum. Compared to the controls MMP-9 levels were lower in sepsis from the fourth day on in serum and both 
the first and fifth day in skin blister fluid. Active forms of MMP-2 and -9 were present only in severe sepsis. The non-
survivors had higher pro- and active MMP-2 levels than the survivors in skin blister fluid samples. Furthermore, MMP-2 
levels were more pronounced in blister fluid and serum samples in patients with more severe organ failures. In the 
survivors at 3 and 6 month follow-up the MMP levels had returned to normal.
Conclusions: MMP-2 and -8 are elevated in serum and blister fluid in severe sepsis, implying that they may play a 
significant role in the pathogenesis of severe sepsis and organ dysfunctions. Active forms of MMP-2 and 9 were only 
present in patients with severe sepsis, and higher MMP-2 levels in skin blister and serum were associated with more 
severe organ dysfunctions.
Introduction
Matrix metalloproteinases (MMPs) are a family of endo-
proteinases that have an important role in the regulation of 
host response, including functions in different phases of 
inflammation and repair. Accordingly, MMPs could play a 
significant role in the massive inflammatory response seen 
in sepsis and resultant organ dysfunctions. Few recent stud-
ies have given insight in to MMP expression in the begin-
ning of human sepsis, but longitudinal studies of the timely 
development of MMP levels in patients with severe sepsis 
and their association to disease severity and outcome have 
not been conducted before. MMP levels at organ level have 
also not been studied in sepsis.
MMPs have been shown to regulate several phases of 
inflammation. For example, MMP-2 and MMP-9 have been 
recently suggested to participate in the cleavage of endothe-
lial tight junction components and thus increase vascular 
permeability and the passage of inflammatory cells and 
mediators to the site of inflammation [1]. Furthermore, 
MMP-8 and MMP-9 can activate and MMP-2 can inacti-
vate chemokines and thus promote recruitment and extrava-
sation of neutrophils to the damaged tissue [2,3]. MMPs 
also modulate the activation of cytokines. MMP-2 and 
MMP-9 seem to be able to release transforming growth fac-
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tor (TGF)-beta from an intracellular complex [4]. However, 
MMP-2, MMP-3 and MMP-9 are not only able to cleave 
IL-beta 1 precursor to the active form but also to attenuate 
the signal by degrading the active form [5,6]. MMP-8 has 
also been suggested to have anti-inflammatory roles in 
experimental mice studies [7,8]. To date there are few stud-
ies reporting the role of MMPs in the beginning of severe 
sepsis in humans. Nakamura and colleagues were the first 
to report evidence of elevated MMP-9 levels with associa-
tion to mortality in sepsis [9]. Hoffmann and colleagues, 
demonstrated elevated plasma levels of MMP-9 and tissue 
inhibitors of matrix metalloproteinases (TIMP)-2, and 
TIMP-1 on the first day of severe sepsis and significantly 
higher TIMP-1 levels in non-surviving patients [10]. 
Recently Lorente and colleagues reported elevated MMP-
10 and TIMP-1 levels in the beginning of severe sepsis 
[11]. Furthermore, in secondary peritonitis and consequent 
septic shock, the MMP-8 levels in peritoneal fluid were 
shown to be increased in the beginning of the disease com-
pared with serum levels [12].
We measured the MMP-2, MMP-8 and MMP-9 levels dur-
ing human severe sepsis and after recovery in serum and 
locally in skin using the suction blister method [13]. Skin is 
one of the organs affected by sepsis and is readily available 
for examination by relatively non-invasive methods. Its 
appropriate function is also of interest, because skin is the 
largest barrier maintaining internal homeostasis. Our 
hypothesis was that levels of MMPs are increased in severe 
sepsis both at systemic and local levels, and that the levels 
are associated with the severity of organ dysfunctions and 
outcome of the patients.
Materials and methods
Patients
This is a substudy of a larger study on connective tissue 
metabolism and wound healing in sepsis. The study group 
consisted of 44 patients with severe sepsis, who were pro-
spectively followed for 10 days from the diagnosis of 
severe sepsis. The study was conducted in a 12-bed mixed-
type adult ICU of Oulu University Hospital, Finland - an 
academic tertiary-level referral hospital. All patients admit-
ted from May 2005 to December 2006 were screened. The 
inclusion criterion was severe sepsis with or without septic 
shock. These were defined according to the American Col-
lege of Chest Physicians/Society of Critical Care Medicine 
criteria [14]. Exclusion criteria included age under 18 years, 
bleeding disorder, immunosuppressant therapy, surgery not 
related to sepsis, surgery during the preceding six months, 
malignancy, chronic hepatic failure, chronic renal failure 
and steroid therapy not related to sepsis. The patients 
entered the study within 48 hours after the first organ dys-
function criterion of severe sepsis was met. The patients 
were treated according to normal ICU protocol and severe 
sepsis guidelines, including steroid supplementation in sep-
tic shock. The study protocol was approved by the hospi-
tal's ethics committee and all the patients or their next of 
kin gave written consent for the study. Fifteen healthy 
adults were used as controls.
Clinical data
The information collected from all the study patients 
included age, sex, chronic diseases, type of ICU admission 
(medical or surgical), reason for admission, focus of infec-
tion, severity of underlying diseases on admission as 
assessed by the Acute Physiology and Chronic Health Eval-
uation II (APACHE II), evolution of daily organ dysfunc-
tions assessed by daily Sequential Organ Failure 
Assessment (SOFA) scores. Organ dysfunction was defined 
as an individual organ SOFA score of one to two and organ 
failure as a SOFA score of three to four. Multiple Organ 
Failure (MOF) was defined as daily SOFA scores of two or 
more organ systems three to four on one or more days dur-
ing the study period. Additively Multiple Organ Dysfunc-
tion Syndrome (MODS) was defined as daily SOFA scores 
of one to two in two or more organ systems on one or more 
days [15]. The length of the ICU and hospital stays as well 
as the ICU, hospital and 30-day mortalities were recorded.
Blood samples
The blood samples were obtained for MMP analysis on 
days 1, 4, 6, 8 and 10 in 10 ml vacuum glass tubes without 
clot activator. In addition, samples from survivors were also 
collected three and six months after recovering from the 
sepsis. Blood samples from the controls were collected 
once. After the centrifugation, the serum was frozen and 
stored at -70°C until the analysis.
Suction blisters
Local MMP concentrations of the skin were assessed ana-
lyzing the suction blister fluid which closely resembles the 
skin interstitial fluid [16]. The skin suction blister method 
has first been described by Kiistala [13] and modified for 
measurement of MMPs by Oikarinen and colleagues [17]. 
The suction blisters were induced on abdominal skin using 
commercially available suction blister devices (Dermovac 
blistering device; Mucel Co., Nummela, Finland) on days 
one and five of the study. The device is 50 mm in diameter 
and contains five pores to which the suction is conducted. 
With prolonged suction five blisters 6 mm in diameter are 
formed. Instantly after the blisters were fully developed the 
blister fluid was collected with 18 G needle and syringe. In 
survivors, suction blisters were also induced three and six 
months after study entry. One set of suction blisters was 
made on the controls. The blister fluid was immediately 
frozen and stored at -70°C until analysis.Gäddnäs et al. Critical Care 2010, 14:R49
http://ccforum.com/content/14/2/R49
Page 3 of 12
Measurements of MMP-2 and MMP-9 by gelatin 
zymography
A 1 μL sample of serum and 2 μL of suction blister fluid 
were used to analyze MMP-2 and MMP -9 in 10% SDS-
PAGE containing 1 mg/ml gelatin labeled fluorescently 
with 2-methoxy-2,4-diphenyl-3(2H)-furanone (Fluka, 
Ronkonkoma, NY, USA) [18]. Low-range prestained SDS-
PAGE Standards (Bio-Rad, Hercules, CA, USA) were run 
in each gel as well as control MMP-2 and MMP -9 samples 
purified from fibroblast and keratinocyte mediums, respec-
tively. Prior to electrophoresis, some suction blister fluid 
samples were incubated with 2 mM 4-aminophenylmercu-
ric acetate (APMA, Sigma Chemical Company, St. Louis, 
MO, USA) at 37°C for one hour. The APMA treatment was 
stopped by adding the electrophoresis sample buffer. After 
electrophoresis, gelatinases were activated by incubating 
the gels for two to three hours at 37°C. As the gelatin used 
in the gels was fluorescently labeled the appearance of the 
gelatinolytic bands during incubation could be monitored 
under long wave UV light. The gels were stained with 0.5% 
Coomassie Brilliant Blue R-250 and the intensities of the 
bands were quantified using optical densitometry and 
Quantity one software (Bio Rad Model GS-700 Imaging 
Densitometer, Bio-Rad, Richmond, CA, USA). The inten-
sity is expressed as densitometric units (dU).
Immunofluorometric assay of MMP-8
The MMP-8 concentrations were determined by a time-
resolved immunofluorometric assay (IFMA). The monoclo-
nal MMP-8 specific antibodies 8708 and 8706 (Medix Bio-
chemica, Kauniainen, Finland) were used as a catching 
antibody and a tracer antibody, respectively. The tracer anti-
body was labeled using europium-chelate [19]. The assay 
buffer contained 20 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 5 
mM CaCl2, 50 μM ZnCl2, 0.5% BSA, 0.05% sodium azide 
and 20 mg/l diethylenetriaminepentaacetic acid (DTPA). 
Samples were diluted in assay buffer and incubated for one 
hour, followed by incubation for one hour with tracer anti-
body. Enhancement solution was added and after five min-
utes fluorescence was measured using a 1234 Delfia 
Research Fluorometer (Wallac, Turku, Finland). The speci-
ficity of the monoclonal antibodies against MMP-8 corre-
sponded to that of polyclonal MMP-8.
Statistical analysis
Serum and blister fluid levels of MMP-8, MMP-9 (92 kDa 
and 82 kDa forms), and MMP-2 (72 kDa and 62 kDa 
forms) were compared between non-surviving and surviv-
ing patients as well as between MODS and MOF patients. 
The time points for the comparisons were on day 1 and 5 
for blister fluid samples and days 1, 4, 6, 8 and 10 for serum 
samples. The serum and blister fluid MMP-levels of MODS 
and MOF patients were additively compared at three and 
six months after recovering sepsis. The comparisons of 
MMPs studied from blister fluid and serum were made also 
between septic patients and controls at each measuring 
point mentioned above. The summary measurements for 
continuous and ordinal variables were expressed as means 
with standard deviation or a median with 25th to 75th percen-
tile. Chi-squared or Fisher's exact test was used for categor-
ical data. Between group comparisons for continuous 
variables were performed using Student's t-test or Mann-
Whitney U test. The linear mixed model was utilized for 
repeated measurement analyses when comparing MODS 
and MOF patients. In the mixed model approach sex, medi-
cal/surgical admission or the use of corticosteroids for the 
treatment of septic shock refractory to vasopressor therapy, 
were used one by one as an adjusting covariate if their 
impact on the model was significant. The P values are 
reported as follows: Pg, indicates a significant level differ-
ence between the groups, Pt+g indicates time-group interac-
tion and Pt indicates the change over time. The statistical 
analyses were performed using SPSS (SPSS, version 16.0, 
SPSS Inc, Chicago, IL, USA) and SAS (version 9.1.3, SAS 
Institute Inc., Cary, NC, USA) statistical software.
Two-tailed significance levels are reported. Readers should 
take into account that where several comparisons are made 
no P value correction coefficient method is used.
Results
Patients
Of the 1,361 patients admitted to the ICU during the period 
from May 2005 to December 2006, 238 adults met the 
inclusion criteria. One hundred and seventy-two patients 
were excluded and 44 of the remaining 66 patients or their 
next of kin gave written informed consent. The control 
group consisted of age- and sex-matched healthy volunteers 
with a median age of 60 years (25th to 75th percentile 56 to 
68 years). Seven of them were females and eight were 
males. The patient demographics and clinical characteris-
tics have been reported previously [20] and are summarized 
in Table 1. The overall median age was 63 years (25th to 
75th percentile 53 to 71 years). The overall median 
APACHE II score at admission was 26 (22 to 30). Of the 
cases, 68% developed MOF and 86% required noradrena-
line and 73% hydrocortisone therapy for septic shock. The 
non-survivors had significantly higher APACHE II score on 
admission and maximum SOFA scores (31 (25th to 75th per-
centile 26 to 37) vs. 24 (22 to 27), P = 0.005 and 16 (11 to 
20) vs. 8 (7 to 11), P = 0.003, respectively). Lungs were the 
most common infection focus and blood culture was posi-
tive in 13 cases.
MMP-8, MMP-2 and MMP-9 in blister fluid in patients and 
healthy controls
The MMP-8 levels in blister fluid samples were signifi-
cantly higher in patients with severe sepsis in comparison Gäddnäs et al. Critical Care 2010, 14:R49
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with the controls on both days (Figure 1). The blister fluid 
levels of the 72 kDa proMMP-2 were slightly elevated on 
both study days (Figure 1). The form spliced to active con-
formation, the 62 kDa MMP-2, was found in all patients 
with severe sepsis on the first day (153.1 dU (53.2 to 
373.9)) and on the fifth day (127.4 dU (47.4 to 318.2)), but 
not in controls (Figure 2). The 92 kDa proMMP-9 was 
lower on both first and fifth day in patients with severe sep-
sis in comparison with the controls (Figure 1). The 82 kDa 
MMP-9, the form spliced to active conformation, was 
found in blister fluid samples of five patients out of 44 on 
the first day and of five patients out of 38 patients on the 
fifth day, but not in control samples (Figure 2). Three and 
six months after severe sepsis no marked differences could 
be observed in comparison with the controls (Figure 1). 
Active form of MMP-2 could be detected in one of the sur-
vivors at three months, and the active form of MMP-9 in 
three survivors at three months and in one even at six 
months.
APMA is an organomercurial activator of MMPs, which 
converts the proMMPs into their active forms by stepwise 
activation. Some blister fluid samples were treated with 
APMA. In samples with APMA-activation the band corre-
sponding to the proform of MMP-2 or MMP-9 weakened 
both in purified control MMP-2 and MMP-9 and in patient 
samples examined. In purified control MMP-2 and MMP-9 
the band corresponding to the active form of MMP-2 or 
MMP-9 strengthened and a weak intermediate-sized band 
appeared between the pro and active forms of MMP-2 or 
MMP-9. In patient samples an intermediate-sized band 
Table 1: Characteristics of the surviving and non-surviving study patients. Categorical variables are presented as 
frequencies with percents and other variables as medians with 25th to 75th percentiles
All (n = 44) Survivors (n = 33) Non-survivors (n 
= 11)
P
Male sex 29 (57%) 20 (60%) 9 (80%) 0.31
Age, years 63 (53-71) 61 (56-66) 71 (62-74) 0.06
Body mass index, kg/m2 26 (24-32) 28 (23-33) 26 (24-27) 0.17
Chronic diseases
-ischemic heart disease 9 (20%) 5 (15%) 4 (36%)
-diabetes 10 (23%) 9 (27%) 1 (9%)
-chronic obstructive pulmonary disease 5 (11%) 4 (12%) 1 (9%)
-asthma 4 (9%) 4 (12%) 0
Focus of infection
-lungs 18 (41%) 13 (39%) 5 (45%)
-intra-abdominal 16 (36%) 12 (36%) 4 (36%)
-urinary 1 (2%) 1 (3%) 0
-primary blood 3 (7%) 2 (6%) 1 (9%)
-other 6 (14%) 5 (15%) 1 (9%)
APACHE II score 26 (22-30) 24 (22-27) 31 (26-37) 0.005
Maximum SOFA score 9.5 (7-16) 8 (7-11) 16 (11-20) 0.003
Multiple organ failure 30 (68%) 20 (60%) 10 (90%) <0.001
Length of stay (at the intensive care unit) 6.6 (4-12) 6 (4-8) 11 (6-14) 0.16
Surgical admission 25 (57%) 18 (55%) 7 (63%) <0.001
Hydrocortisone therapy 32 (73%) 22 (67%) 10 (90%) <0.001
Noradrenaline
maximum rate, μg/kg/min
38 (86%)
0.42(0.19-1)
27 (82%)
0.25(0.09-0.43)
11 (100%)
0.96 (0.53-1.80)
0.13
0.005
Adrenaline 1 (2%) 1(3%) 0 0.56
Vasopressin and analogues 6 (14%) 3 (9%) 3 (27%) 0.15
Activated protein C 6 (14%) 3 (9%) 3 (27%) 0.13
APACHE, Acute Physiology and Chronic Health Evaluation II score; SOFA, Sequential Organ Failure Assessment.Gäddnäs et al. Critical Care 2010, 14:R49
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between the pro and active forms of MMP-2 or MMP-9 
appeared while the band for the active form of MMP-2 or 
MMP-9 was not significantly altered (Figure 2d).
MMP-8, MMP-2 and MMP-9 in serum in patients and 
healthy controls
Also in the serum samples MMP-8 was found to be ele-
vated during the ten day study period and the 72 kDa 
proMMP-2 was elevated until the sixth day in comparison 
with the controls (Figure 1). Interestingly, the 92 kDa 
proMMP-9 levels were lower in the serum of sepsis patients 
Figure 1 MMP-8, proMMP-2 (62 kDa) and proMMP-9 (92 kDa) levels in patients with severe sepsis and in healthy controls. Results from the 
suction blister samples are on the left and from the serum samples on the right. Panel A presents the control value, panel B the values of all the patients 
in severe sepsis and panel C the values of the surviving patients at three and six months after severe sepsis. The diagonal lines mark the range from 
25th to 75th percentile. Statistically significant differences between the control values and the values of the patients at each measuring point are 
marked with asterisks above the values of the patients (* P < 0.05, ** P < 0.01, *** P < 0.001). The development of patient number (N) is expressed below 
the figure. MMP, matrix metalloproteinase.Gäddnäs et al. Critical Care 2010, 14:R49
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in comparison to healthy controls during the 10 days (Fig-
ure 1). The 62 kDa MMP-2 could not be detected in the 
serum samples in patients and controls and the 82 kDa 
MMP-9 could be detected only in few samples (3 on day 1; 
4 on day 4; 5 on days 6, 8 and 10; and 0 at 3 and 6 months). 
At three and six months after the sepsis, the levels of the 
survivors were similar to those of the controls (Figure 1).
Survivors in comparison with non-survivors
Blister fluid proMMP-2 levels were significantly higher in 
non-survivors in comparison with survivors on both first 
and fifth days (1132.2 dU (922.1 to 1405.1) vs. 701.99 dU 
(604.7 to 941.1), P = 0.001 and 1153.9 dU (801.9 to 
1349.4) vs. 735.9 dU (627.4 to 888.6), P = 0.01, respec-
tively). ProMMP-9 form in blister fluid was higher in non-
survivors on the first but not the fifth day (365.4 dU (221.0 
to 478.3) vs. 102.8 dU (60.8 to 273.75), P = 0.005 and 
151.6 dU (37.5 to 231.5) vs. 127.9 dU (47.8 to 283.4), P = 
0.84, respectively). MMP-8 levels were similar in both 
groups of non-survivors and survivors on both days (28.8 
ng/ml (8.2 to 84.7) vs.12.8 ng/ml (5.2 to 52.8), P = 0.47 and 
13.5 ng/ml (6.6 to 4.1) vs. 20.7 ng/ml (4.6 to 67.4), P = 
0.84, respectively). In serum samples, there were no signifi-
cant differences in the levels of MMP-8, proMMP-9 and 
proMMP-2 between survivors and non-survivors (data not 
shown).
Patients with MODS in comparison to patients with 
multiple organ failure
Patients with MODS were compared with those having 
MOF with a linear mixed model. In skin blister fluid the 
timely development of the levels of MMP-8 did not differ 
between the groups during the study (data not shown). The 
proMMP-2 was higher on the first and fifth day in patients 
with MOF in comparison with MODS (935.6 dU (707.8 to 
1220.8) vs. 659.3 dU (572.5 to 700.5), P = 0.002 and 790.0 
dU (719.3 to 1092.85) vs. 641.44 dU (719.3 to 1092.85), P 
= 0.01, respectively). The active 62 kDa form was signifi-
cantly higher in patients with MOF than in MODS on the 
first and fifth days (224.91 dU (57.1 to 502.6) vs. 69.3 dU 
(6.06 to 174.8), P = 0.03 and 239.2 dU (84.5 to 412.9) vs. 
46.1 dU (18.02 to 79.3) P = 0.001, respectively). The 
Figure 2 MMP-2 and MMP -9 levels in suction blister fluids of patients with severe sepsis and healthy controls were measured by gelatin 
zymography. All the gels had matrix metalloproteinase (MMP)-2 and MMP-9 samples purified from fibroblast and keratinocyte mediums, respectively. 
(a) MMP-2 and MMP-9. Pro and active forms of MMP-2 and MMP-9 are shown by arrows. As the running time for different gels varied slightly the bands 
are not exactly at the same level in samples analyzed in different gels. Three different healthy control samples (C1, C2, C3) are shown together with 
purified control MMP-2 and MMP-9. (b) Samples from two different surviving patients (P1, P2) are shown. For each of them one and five days and three 
and six month samples were run side by side in the gel. (c) Samples from four different non-surviving patients (P 3 to P 6) on days one and five (run 
side by side in the gel for each of them) are shown. (d) Purified control MMP-2 and MMP-9 and two different patient samples (P7, P8) incubated with 
(+) or without (-)4-aminophenylmercuric acetate (APMA) are shown (each sample with and without APMA was run side by side in the gel). In samples 
with APMA activation the bands corresponding to the proforms are weakened. Asteriks indicates the intermediate sized MMP-2 or MMP-9.Gäddnäs et al. Critical Care 2010, 14:R49
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proMMP-9 levels were higher in MOF than in MODS in 
the beginning of the study (225.2 dU (93.6 to 463.9) vs. 
91.5 dU (57.7 to 227.0), P = 0.05; Figure 3).
In the serum samples the MMP-8 levels were slightly ele-
vated from day 6 to 10 in patients with MOF compared with 
MODS, thus the timely development differed in these 
groups. The proMMP-2 values in the MOF group were 
higher especially at the beginning of the study. The levels 
and timely development of proMMP-9 did not significantly 
differ between patients with MOF and MODS (Figure 4).
Correlations with organ dysfunction parameters
No correlations between APACHE II score on admission 
and MMP-2, MMP-8 and MMP-9 were found at any time 
point. Instead several positive correlations were found with 
the daily SOFA scores. Blister fluid proMMP-2 on the first 
day correlated positively with SOFA scores on days 1 to 8 
and proMMP-2 on the fifth day with SOFA scores on days 
1 to 10. Similarly active MMP-2 blister fluid levels on day 
one and five correlated with SOFA scores on several days 
(Table 2). Also the serum levels of proMMP-2 correlated 
with SOFA scores. Correlations with serum proMMP-2 on 
day one were found with SOFA scores from days one to 
five and for proMMP-2 on day four with SOFA scores from 
days one to six. (Table 3). No correlation between daily 
SOFA scores and MMP-8 levels of blister fluid or serum 
were found. On day one blister fluid or serum proMMP-9 
did not correlate to SOFA at any time point, but the blister 
fluid level on the fifth day correlated negatively with SOFA 
on day two (-0.04, P = 0.03) and serum level of day four 
with SOFA on day one (-0.36, P = 0.03).
Discussion
This is the first longitudinal study reporting the levels of 
MMP-2, MMP-8 and MMP-9 in the patients with severe 
sepsis. The main findings were the levels of MMP-2 and 
MMP-8 were up-regulated in severe sepsis both in skin 
blister fluid and in the serum, MMP-2 levels were higher in 
skin blister fluid as well as in serum in more severe organ 
failures, and at three and six months the MMP levels had 
returned to normal.
Similar to our results, increased MMP-8 levels have also 
been observed in a study with peritonitis patients, the 
majority of who had septic shock [12]. MMP-8, also called 
the neutrophil collagenase, is predominantly released from 
neutrophilic granules upon infectious stimuli. However, in 
sepsis patients neutrophil infiltration to experimental skin 
blisters has shown to be attenuated by inflammatory media-
tors that down-regulate chemotactic receptors on neutro-
phils [21]. Hence, the increased MMP-8 levels compared 
with controls seen in blister fluid possibly originate from 
circulating and marginated neutrophils, and translocates to 
the blister, or arise from other known cellular sources [22]. 
Our studies did not reveal the source, but demonstrate, that 
in severe sepsis MMP-8 is up-regulated even in healthy 
looking skin. Additively MMP-8 is not associated with 
organ failure parameters thus supporting the suggestion that 
MMP-8 has both pro- and anti-inflammatory roles.
Surprisingly, in our data the 92 kDa proMMP-9 levels were 
suppressed in serum from the fourth day on and in the suc-
tion blister fluid from the first day. Even when active and 
pro forms were calculated together the levels were sup-
pressed in sepsis in comparison with the control samples 
(data not shown). Previously elevated MMP-9 levels have 
been reported within 24 hours from severe sepsis diagnosis 
[9-11]. We collected the first samples within 48 hours from 
Figure 3 MMP-2 (pro 72 kDa and active 62 kDa forms) and MMP-9 (pro 92 kDa form) levels in blister fluid of patients with multiple organ 
dysfunction syndrome (MODS) and multiple organ failure (MOF). Panel A presents the values of all the patients in severe sepsis and panel B the 
values of survivors at three and six months. P values from comparison of MODS and MOF patients with the linear mixed model are expressed above: 
Pg difference between the groups, Pt-g difference in time-group interaction, Pt difference in change over time. MMP, matrix metalloproteinase.Gäddnäs et al. Critical Care 2010, 14:R49
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the beginning of the disease. The MMP-9 levels have been 
shown to peak early in lipopolysaccharide and Escherichia 
coli-induced inflammatory response and return to normal 
within 24 hours [23,24]. In the largest of previous patient 
samples MMP-9 was not significantly higher in sepsis 
patients and a negative correlation was found to organ fail-
ure parameters [11]. This is in accordance with our results 
from the first study day. Our results on lower levels of 
MMP-9 from study day four are on another hand a novel 
finding. Forms spliced to active MMP-9 could be found in a 
few patient samples but not in controls, implying that 
MMP-9 had been processed, whereas from day four 
onwards, the proMMP-9 levels dropped in a regulative 
fashion. Taken together, it seems that the MMP-9 levels are 
elevated at the very early phase of severe sepsis, but the 
levels drop later on.
We found low MMP-9 levels also in skin blister fluid sam-
ples of patients with severe sepsis in comparison with the 
controls. This is in accordance with the growing body of 
evidence suggesting that neutrophil migration to tissues is 
impaired in sepsis [25]. The interesting finding that MMP-9 
levels were higher in non-survivor sample in the blister 
fluid at only the first day might be due to sepsis-induced 
damage on the structures of healthy looking skin, observed 
clinically as edema and even as spontaneous blistering in 
most severe forms of sepsis. This hypothesis is supported 
by the findings that elevated MMP-9 levels have been 
shown in spontaneous blistering diseases and that MMP-9 
during tissue healing seems to enable migration of epithe-
lial cells by degrading collagen IV, an important component 
of dermoepidermal junctions [17]. In blister fluid samples 
of healthy looking skin the proMMP-2 form was elevated 
and the active form was found constantly in sepsis, but not 
in control samples. This is surprising in the light of previ-
ous evidence that shows that MMP-2 expression is absent 
in healthy skin except some sweat glands, hair follicles and 
macrophages [26]. The factors that have been shown to 
induce MMP-2 expression in human skin include skin 
injury [26], TNF-alpha, and TGF-beta [27]. In addition, 
endothelial damage and reactive oxygen species present in 
sepsis can trigger the activation of MMP-2. Elevated con-
centrations of MMP-2 are associated with septic organ 
damage in skin, heart and lung [28-30]. However MMP-2 
seems to have both beneficial and detrimental roles in 
inflammation. Based on our data, the levels of MMP-2 in 
blister fluid samples were higher in non-survivors and we 
have previously shown that re-epithelization of blister 
wounds is delayed in non-surviving severe sepsis patients 
[28].
Some medications used in sepsis, including vasopressor 
agents, hydrocortisone and activated protein C (APC), have 
been shown to affect MMP expression [29,31-33]. The 
elimination of these clinically central therapies from a study 
setting with patients with severe sepsis would be impossi-
ble, and thus their role must be acknowledged when evalu-
ating the results. In this study 86% of patients received 
noradrenaline, 73% hydrocortisone and 14% APC. In an 
ovine model of septic cardiac failure, MMP-2 levels were 
shown to be even higher in noradrenaline-masked hypov-
olemia added to endotoxemia than in endotoxemia alone 
[29]. APC reduced the MMP-9 levels in fibroblasts and 
monocytes of arthritis patients, but up-regulated and acti-
vated MMP-2 [32]. In human keratinocytes APC enhanced 
the expression and activation of MMP-2, but had no effect 
on MMP-9 [31].
This study is limited by the fact that the precise phase of 
inflammation was not determined on the molecular level, 
but from the beginning of the organ failure. This would be 
beneficial in the future studies, because the timing of up- 
and down-regulation of different inflammatory mediators 
will help to create a more coherent understanding on the 
events of septic host response. Secondly, we used healthy 
Figure 4 pro MMP-2, MMP-8 and pro MMP-9 levels in serum of patients with multiple organ dysfunction syndrome (MODS) and multiple 
organ failure (MOF). Panel A presents the values of all the patients in severe sepsis and panel B the values of survivors at three and six months. P 
values from comparison of MODS and MOF patients with the linear mixed model are expressed above: Pg difference between the groups, Pt-g differ-
ence in time-group interaction, Pt difference in change over time. MMP, matrix metalloproteinase.G
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Table 2: Correlations between blister fluid pro-MMP2 and active MMP-2 and daily SOFA scores
SOFA day 
1
SOFA day 
2
SOFA 
day3
SOFA day 
4
SOFA day 
5
SOFA day 
6
SOFA day 
7
SOFA day 
8
SOFA day 
9
SOFA 
day10
proMMP-2 
day 1 (dU)
rho 0.570** 0.504** 0.569** 0.501** 0.522** 0.536** 0.612** 0.580** 0.392 0.216
p 0.000 0.000 0.000 0.002 0.003 0.008 0.002 0.005 0.133 0.421
N 44 44 38 35 31 23 23 22 16 16
proMMP-2 
day 5 (dU)
rho 0.394* 0.486** 0.525** 0.495** 0.576** 0.577** 0.596** 0.676** 0.633* 0.545*
p 0.014 0.002 0.001 0.004 0.001 0.006 0.004 0.001 0.015 0.044
N 38 38 34 32 29 21 21 20 14 14
actMMP-2 
day 1 (dU)
rho 0.576** 0.493** 0.401* 0.238 0.232 0.436* 0.439* 0.437* 0.153 0.005
p 0.000 0.001 0.013 0.168 0.210 0.038 0.036 0.042 0.571 0.986
N 44 44 38 35 31 23 23 22 16 16
actMMP-2 
day 5 (dU)
rho 0.565** 0.540** 0.551** 0.364* 0.479** 0.537* 0.570** 0.488* 0.525 0.438
p 0.000 0.000 0.001 0.040 0.009 0.012 0.007 0.029 0.054 0.118
N 38 38 34 32 29 21 21 20 14 14
SOFA, Sequential Organ Failure Assesment score; MMP, matrix metalloproteinase; dU, densitometric units; rho, Spearman's rank correlation coefficient. * P < 0.5, **P < 0.01.G
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Table 3: Correlations between serum proMMP-2 and daily SOFA-scores
SOFA day 
1
SOFA day 
2
SOFA 
day3
SOFA day 
4
SOFA day 
5
SOFA day 
6
SOFA day 
7
SOFA day 
8
SOFA day 
9
SOFA 
day10
proMMP-2 
day 1 (dU)
rho 0.0.480** 0.0.519** 0.0.547** 0.0.490** 0.0.408* 0.0.402 0.0.342 0.0.349 0.0.207 0.0.022
p 0.0.001 0.0.000 0.0.000 0.0.003 0.0.023 0.0.057 0.0.110 0.0.112 0.0.441 0.0.934
N 44 44 38 35 31 23 23 22 16 16
proMMP-2 
day 4 (dU)
rho 0.0.423* 0.0.468** 0.0.512** 0.0.540** 0.0.431* 0.0.480* 0.0.352 0.0.350 0.0.451 0.0.471
p 0.0.011 0.0.005 0.0.002 0.0.003 0.0.022 0.0.020 0.0.100 0.0.110 0.0.079 0.0.065
N 35 35 33 29 28 23 23 22 16 16
proMMP-2 
day 6 (dU)
rho 0.0.343 0.0.400* 0.0.350 0.0.394 0.0.253 0.0.247 0.0.084 0.0.059 0.0.354 0.0.293
p 0.0.063 0.0.028 0.0.068 0.0.051 0.0.223 0.0.308 0.0.723 0.0.805 0.0.196 0.0.290
N 30 30 28 25 25 19 20 20 15 15
proMMP-2 
day 8 (dU)
rho 0.0.563** 0.0.477* 0.0.517* 0.0.567** 0.0.441* 0.0.421 0.0.374 0.0.341 0.0.386 0.0.512
P 0.0.003 0.0.016 0.0.012 0.0.007 0.0.040 0.0.092 0.0.126 0.0.166 0.0.155 0.0.051
N 25 25 23 21 22 17 18 18 15 15
proMMP-2 
day 10 (dU)
rho 0.0.472* 0.0.435 0.0.422 0.0.440 0.0.259 0.0.273 0.0.170 0.0.215 0.0.389 0.0.650*
P 0.0.048 0.0.071 0.0.092 0.0.088 0.0.316 0.0.366 0.0.560 0.0.460 0.0.238 0.0.030
N 18 18 17 16 17 13 14 14 11 11
SOFA, Sequential Organ Failure Assesment score; MMP. matrix metalloproteinase; dU, densitometric units; rho, Spearman's rank correlation coefficient. *P < 0.50. *P < 0.01.Gäddnäs et al. Critical Care 2010, 14:R49
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controls instead of critically ill patients. Systemic inflam-
matory response can be activated also from other reasons 
than infectious insult and is very common in ICU patients, 
especially in surgical ICUs [34]. Thus we considered it 
more reasonable to use healthy controls. Thirdly the num-
ber of patients was too small for a reliable statement about 
MMPs as prognostic markers in patients with sepsis.
Conclusions
In severe sepsis, from intact skin suction blister and serum 
samples, MMP-2 and MMP-8 levels are elevated, whereas 
MMP-9 is suppressed. Active forms of MMP-2 and MMP-
9 are only found in some patients with severe sepsis, but not 
in controls. The non-survivors had higher pro and active 
MMP-2 levels in the skin blister fluid than the survivors, 
and MMP-2 levels both in serum and skin blister fluid were 
more pronounced in patients with more severe organ fail-
ures.
Key messages
• Levels of MMP-2 and MMP-8 were up-regulated in 
severe sepsis in comparison with healthy controls, both 
in skin blister fluid and in the serum, whereas MMP-9 
levels were lower in serum in sepsis from the fourth day 
onwards.
• Non-surviving patients had higher MMP-2 levels in 
skin blister fluid during sepsis than survivors. Further-
more, MMP-2 levels were more pronounced in skin 
blister fluid as well as in serum in more severe organ 
failures.
• MMP-2 levels in serum and blister fluid correlated 
with daily SOFA scores.
• At the follow-up samples from surviving patients at 
three and six months the levels of MMP-2, MMP-8 and 
MMP-9 were near to normal.
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